Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks

InvestorPlace07-25

Morgan Stanley (MS) analysts only rate a handful of high-growth stocks as growing 100% or more over the next 12 months. Li Auto (LI): The Chinese EV maker beat analyst expectations on Q2 deliveries ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2454286518?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-25 18:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454286518","market":"us","top_or_hot":-1,"title":"Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks","media":"InvestorPlace","content":"<div>\n<p>Morgan Stanley (MS) analysts only rate a handful of high-growth stocks as growing 100% or more over the next 12 months.\nLi Auto (LI): The Chinese EV maker beat analyst expectations on Q2 deliveries ...</p>\n\n<a href=\"https://investorplace.com/2024/07/morgan-stanley-predicts-triple-digit-rally-for-these-3-stocks/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley Predicts Triple-Digit Rally for These 3 Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-25 18:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2024/07/morgan-stanley-predicts-triple-digit-rally-for-these-3-stocks/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Morgan Stanley (MS) analysts only rate a handful of high-growth stocks as growing 100% or more over the next 12 months.\nLi Auto (LI): The Chinese EV maker beat analyst expectations on Q2 deliveries ...</p>\n\n<a href=\"https://investorplace.com/2024/07/morgan-stanley-predicts-triple-digit-rally-for-these-3-stocks/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765059.SGD","symbol_name":"FTIF - Franklin US Opportunities A Acc SGD","start_time":0,"source_url":"https://investorplace.com/2024/07/morgan-stanley-predicts-triple-digit-rally-for-these-3-stocks/","article_id":"2454286518","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454286518","pubTimestamp":1721902080,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"Morgan Stanley  analysts only rate a handful of high-growth stocks as growing 100% or more over the next 12 months.Li Auto : The Chinese EV maker beat analyst expectations on Q2 deliveries but will delay delivering a new SUV until 2025.Silence Therapeutics : Using RNAi therapies to deliver treatment for rare diseases holds significant growth potential.Viking Therapeutics : The biotech is pursuing weight loss in pill form, arguably the gold standard for treating obesity.Below are three high-growth stocks Morgan Stanley  analysts see growing by 100% over the next year. Let’s see if these are grounded expectations or just wishcasting.Still, Hsiao believes the selloff in LI stock was overdone. So, although he lowered his price target, it still implies a 168% upside potential in the stock.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","VKTX":"Viking Therapeutics, Inc.","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","MS":"摩根士丹利","BK4588":"碎股","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","SLN":"Silence Therapeutics Plc","LLY":"礼来","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4581":"高盛持仓","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4504":"桥水持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0079474960.USD":"联博美国增长基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","BK4548":"巴美列捷福持仓","BK4563":"昨日强势股","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","BK4127":"投资银行业与经纪业","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","EVS.SI":"MSCI China Electric Vehicles and Future Mobility ETF-NikkoAM","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","NVO":"诺和诺德","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LI":"理想汽车","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4534":"瑞士信贷持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药"},"translate_title":"摩根士丹利预测这三只股票将出现三位数上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1,"SLN":1,"MS":1,"LI":1,"NVO":0.6,"EVS.SI":0.6,"LLY":0.6},"content_text":"Morgan Stanley (MS) analysts only rate a handful of high-growth stocks as growing 100% or more over the next 12 months.\nLi Auto (LI): The Chinese EV maker beat analyst expectations on Q2 deliveries but will delay delivering a new SUV until 2025.\nSilence Therapeutics (SLN): Using RNAi therapies to deliver treatment for rare diseases holds significant growth potential.\nViking Therapeutics (VKTX): The biotech is pursuing weight loss in pill form, arguably the gold standard for treating obesity.\n\n\n\n\n\n \n\nSource: Golden Dayz / Shutterstock.com\n\n\n\nWall Street likes to peer into the fog of the future and guess where a stock is headed. While these stock price predictions are based on educated estimates, often based on information and models unavailable to regular investors, they are nonetheless guesses.\nAnalyst price targets are short-term in nature. They tend to look out for 12 months or so. Investors shouldn’t weigh too much on these opinions as stock prices can be volatile over such short periods. An investor should seek to own a stock for at least three to five years, preferably a decade or longer.\nStill, when analysts peg high-growth stocks to double or more in a year, it is worth noting. After all, even if they are wrong by half, it could amount to some serious gains. But that also means if you have chosen a stock because you think it has long-term potential, I wouldn’t sell it just because it reached an analyst’s arbitrary price target. Letting your winners run is solid investment advice that has proven its worth over time. \nBelow are three high-growth stocks Morgan Stanley (NYSE:MS) analysts see growing by 100% over the next year. Let’s see if these are grounded expectations or just wishcasting. \nLi Auto (LI)\nSource: Robert Way / Shutterstock.comChinese electric vehicle manufacturer Li Auto (NASDAQ:LI) is the first high-growth stock that more than one analyst sees doubling in value. Morgan Stanley analyst Tim Hsiao has a market-high target price of $53 per share despite his lower outlook of $65 per share.\nLI stock is down 47% in 2024 as the slowing EV market even hit China’s automakers. Yet June deliveries across the industry surprised the market with its strength. Second quarter numbers were much more robust than anticipated.\nThe EV maker delivered 47,774 vehicles in June, up 47% from last year and slightly ahead of expectations for 47,000. Li also reported selling 108,600 EVs in the second quarter, better than the midpoint of the range it provided in May of 105,000 to 110,000 vehicles. With Li expected to report its financials in late August, Hsiao said he cut his price target to reflect “Li Auto’s strategic product pipeline changes.” \nThat is based on Li’s decision to delay releasing a pure electric SUV this year. The automaker has pushed back the timeline to the first half of 2025.\nStill, Hsiao believes the selloff in LI stock was overdone. So, although he lowered his price target, it still implies a 168% upside potential in the stock.\nSilence Therapeutics (SLN)\nSource: shutterstock.com/Lemonsoup14British biotech Silence Therapeutics (NASDAQ:SLN) is the second high-growth stock with triple-digit percentage return potential. Morgan Stanley analyst Michael Ulz has an overweight rating on the stock and raised his price target last month from $45 per share to $49, implying a 129% upside. Yet that is somewhat below the consensus outlook on the stock, with a price target of $61.50 per share or 186% above current levels. \nSilence wants to use precision-engineered medicines using RNA interference (RNAi). It is the body’s natural mechanism of “silencing” the expression of genes that cause disease. Its lead drug candidate is zerlasiran (SLN360), currently in Phase 2 clinical trials. Silence recently reported positive results from a 48-week study of 178 patients with elevated lipoprotein(a), which indicates a high risk of atherosclerotic cardiovascular disease. It said Zerlasiran was well tolerated and had no serious safety concerns. \nBiotech’s stock has been up 23% this year but has tripled over the last 12 months. In February, it received a $10 million milestone payment from AstraZeneca (NYSE:AZN), which is collaborating on various cardiovascular, renal, and metabolic diseases. As part of the collaboration, it can pursue 10 targets. Silence is eligible for up to $140 million in development milestones and up to $250 million in commercialization milestones. It will also receive tiered royalties on net sales when they occur.\nViking Therapeutics (VKTX)\nSource: ra2 studio/ShutterstockAnother biotech with high-growth potential is Viking Therapeutics (NASDAQ:VKTX). It is making a name for itself in the obesity drug market, which was popularized by Ozempic and Wegovy from Novo Nordisk (NYSE:NVO) and Monjouro and Zepbound from Eli Lilly (NYSE:LLY). \nViking seeks to stake out a new path by making a therapy in pill form. Because the competition requires regular injections, pills are a less optimal treatment for diabetes and obesity. Weight loss in a pill is something of the Holy Grail in public acceptance, and Viking’s GLP-1 treat called VK2735 could open it to a massive opportunity.\nMorgan Stanley’s Ulz also covers Viking, and he set a $105 per share price target for biotech. That suggests a 121% upside for VKTX stock.\nShares are down 47% from the highs they hit on early positive results from VK2735, but they remain 182% higher in 2024 and are more than 240% above where the stock stood a year ago.\nOn the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\nOn the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.\nRich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L’Express, and numerous other news outlets.Growth Stocks\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2024/07/morgan-stanley-predicts-triple-digit-rally-for-these-3-stocks/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.3","shortVersion":"4.26.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454286518"}